IO Biotech Completes Oversubscribed EUR 127 Million Series B Financing to Accelerate Clinical Programs in Oncology

by | Jan 13, 2021

IO Biotech, a clinical-stage biopharmaceutical company developing novel, immune- modulating anti-cancer therapies based on its proprietary T-win® technology, announced today that it has raised EUR 127 million in Series B financing.

Press inquiries should be adressed to:

Claus Andersson, PhD

General Partner